AFXA.F Stock — Price, Charts & Analysis

Carl Zeiss Meditec AG (AFXA.F) has a trailing P/E of 23.07x. This places AFXA.F in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

AFXA.F trades with 23.07x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether AFXA.F looks overvalued or undervalued.

AFXA.F's P/E of 23.07x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

AFXA.F's trailing EPS is €1.37. Reported earnings growth is 97.50%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Carl Zeiss Meditec AG generated for each share. AFXA.F's trailing EPS is €1.37, and investors usually prefer EPS that is positive and growing over time.

Carl Zeiss Meditec AG has a market cap of €2.77B, making AFXA.F a mid-cap stock based on the current market value shown on Worldtickers.

AFXA.F's latest stock price on Worldtickers is €31.60. The latest move is -€0.20 or -0.63%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

AFXA.F's quote includes a latest price of €31.60. The market open is €31.60. Previous close is €31.80. The intraday range is €31.60 to €31.60.

AFXA.F is down in the latest quote, with a move of -€0.20 or -0.63%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

AFXA.F generated €2.18B in trailing revenue. Revenue growth is 2.40%, which helps show whether demand is expanding or slowing.

AFXA.F's revenue growth is 2.40%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, AFXA.F shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is €121.51M.

Gross margin is 51.56%. Margins show how efficiently Carl Zeiss Meditec AG turns revenue into profit.

Carl Zeiss Meditec AG carries €580.95M and holds €23.90M in cash.

AFXA.F holds €23.90M on its balance sheet.

AFXA.F's book value per share is €24.18.

Yes, Carl Zeiss Meditec AG pays a dividend of €0.53 per share annually. The dividend yield is 170.00%. The payout ratio is 43.60%.

AFXA.F's dividend yield is 170.00%. Its payout ratio is 43.60%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for AFXA.F. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Carl Zeiss Meditec AG's investor relations materials.

AFXA.F's five-year average dividend yield is 113.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 0.00% of AFXA.F shares. Insiders hold 0.00% of shares. Ownership mix helps investors understand how much of Carl Zeiss Meditec AG is held by professional investors and company insiders.

AFXA.F has 87.54M shares outstanding. Float shares are 34.19M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for AFXA.F, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Earnings growth is 97.50%. Revenue growth is 2.40%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

AFXA.F's trailing EPS is €1.37. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

AFXA.F is in the Healthcare sector. Its earnings multiple is 23.07x. Its latest displayed growth metric is 2.40%. Compare these figures with sector peers before deciding whether Carl Zeiss Meditec AG is stronger or weaker than average.

AFXA.F trades at €31.60. The stock trades at 23.07x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Carl Zeiss Meditec AG's fundamentals.

AFXA.F risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.35, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

AFXA.F should be compared with companies in Medical Instruments & Supplies. Its earnings multiple is 23.07x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Carl Zeiss Meditec AG (AFXA.F) operates in Healthcare, specifically Medical Instruments & Supplies. Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical

AFXA.F trades on Frankfurt. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

AFXA.F stock is priced in EUR on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Carl Zeiss Meditec AG's official website listed on Worldtickers is www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Carl Zeiss Meditec AG employs about 5.78K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Carl Zeiss Meditec AG is headquartered in Jena, Germany. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

AFXA.F is in the Healthcare sector and the Medical Instruments & Supplies industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

AFXA.F has traded between €22.00 and €48.60 over the past 52 weeks. At €31.60, it is 34.98% below the high and 43.64% above the low. The 52-week range helps gauge long-term price momentum.

AFXA.F is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is €28.35 and its 200-day moving average is €29.91.

AFXA.F's RSI is 59.94. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

AFXA.F's latest RSI reading is 59.94, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for AFXA.F is near €27.00. Key resistance is near €31.40. Breaks above resistance or below support can change the short-term technical setup.

AFXA.F's nearest reported support level is €27.00. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

AFXA.F's nearest reported resistance level is €31.40. A breakout above resistance can improve momentum, especially when volume confirms the move.

AFXA.F trades about 59 shares daily on average. The latest displayed volume is 50 shares. Volume helps show liquidity and whether trading interest is unusually high or low.

AFXA.F's MACD is 0.10, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

AFXA.F is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 59.94 (neutral). MACD is bullish. Nearest support is around €27.00. Resistance is around €31.40. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is €29.84 (5.90% from price). MA50 is €28.35 (11.46% from price). MA200 is €29.91 (5.65% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. AFXA.F's MA20 is €29.84. MA50 is €28.35. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

AFXA.F's pivot is near €31.20. Support is near €27.00. Resistance is near €31.40. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for AFXA.F is near €30.76. These levels help define risk and possible follow-through zones after a breakout or breakdown.

AFXA.F's Bollinger range is roughly €27.24 to €32.44. Band width is near 17.45%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

AFXA.F's ATR-based typical daily range is about 2.87%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 50 shares. Average volume is about 59 shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

AFXA.F's all-time high shown on Worldtickers is €200.00. Its all-time low is €22.00. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

AFXA.F has a beta of 1.35, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.